Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01822678
Recruitment Status : Completed
First Posted : April 2, 2013
Results First Posted : August 2, 2013
Last Update Posted : March 27, 2014
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
Multicentre, double-blind, randomised, parallel-group, placebo-controlled dose-titration study; depending on clinical efficacy, up-titration of dosage 3 and 6 days after start of treatment; maintenance of individual maximum dose for the rest of the total 3-week treatment period; subsequently, down-titration (according to the dose steps and the time intervals of up-titration) and administration of an established anti-manic therapy during the tapering-off period (in patients who discontinued treatment) or entry into a recurrence prevention study (Protocol PRA+SCO/BIA-2093-205; reported under separate cover) as an option for patients who responded to the study treatment

Condition or disease Intervention/treatment Phase
Bipolar I Disorder Drug: Eslicarbazepine Acetate Drug: Placebo Phase 2

Detailed Description:

Objectives:

The primary objective was to evaluate the dose-dependent efficacy of 2 dose-titration regimens of Eslicarbazepine Acetate (ESL) compared with placebo as therapy in patients with acute mania.

The secondary objective was to evaluate the safety and tolerability of 2 dose-titration regimens of Eslicarbazepine Acetate in comparison to placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 161 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial
Study Start Date : December 2005
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
Drug: Eslicarbazepine Acetate
Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
Other Name: Eslicarbazepine Acetate tablets

Experimental: Group 2
Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
Drug: Eslicarbazepine Acetate
Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
Other Name: Eslicarbazepine Acetate tablets

Placebo Comparator: Group 3
Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
Drug: Placebo
Placebo
Other Name: sugar pill




Primary Outcome Measures :
  1. Change in the Young Mania Rating Scale (YMRS) Total Score at the End of the 3-week Treatment Period, in Relation to the Baseline. [ Time Frame: baseline and 3-week ]
    The YMRS is used to assess disease severity in patients who have been previously diagnosed with mania and it has proven psychometric properties through 11 item multiple-choice diagnostic questionnaire and the total score is determined from the summation of each 11 individual scores (and can range from 0 - 60) based on the patient's subjective feedback of his clinical condition over the previous 48 hours. A higher score indicates a worse rating for symptoms related to mania. At every visit throughout the study, investigators administered the YMRS. The results of the primary analysis of efficacy were calculated using Analysis of covariance (ANCOVA) with Last Observation Carried Forward (LOCF). Primary variable is presented through ANCOVA results for absolute change in YMRS total score from baseline (V2) to end of treatment (V7). A responder has at least 50% improvement (reduction) in the YMRS total score or has a total score of less than 12 points at the end of treatment period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aged ≥18 years;
  • a documented diagnosis of bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (i.e., 296.0, 296.4 or 296.6) [8];
  • currently displaying an acute manic (including mixed) episode according to the DSM-IV criteria;
  • a Young Mania Rating Scale (YMRS) total score of ≥20;
  • symptoms of the current manic episode starting within 2 weeks prior to randomisation (V2, Day 1);
  • able to undergo a standard evaluation, including clinical interview, ratings and laboratory studies;
  • signed informed consent form;
  • post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation; women of childbearing potential had to present a serum pregnancy test consistent with a non-gravid state and had to use double-barrier contraception until the post-study visit (PSV).

Exclusion Criteria:

  • a history of schizophrenia or schizoaffective disorder, psychotic features or rapid cycling;
  • currently treated with carbamazepine or oxcarbazepine;
  • a history of unresponsiveness, intolerance or hypersensitivity to related compounds (carbamazepine, oxcarbazepine or licarbazepine);
  • use of any depot-neuroleptics for the current manic episode;
  • abuse of stimulating drugs or use of any systemic sympathicomimetic drug within the previous 2 weeks;
  • electroconvulsive therapy within the previous 3 months;
  • a history of dependence or chronic abuse from alcohol, drugs or medications within the last year;
  • judged clinically to be at risk of harm to self or others;
  • second or third-degree atrioventricular blockade not corrected with a pacemaker;
  • relevant electrocardiogram (ECG) or laboratory abnormalities;
  • calculated creatinine clearance <30 mL/min [men: (140-age) x weight / serum creatinine x 72; women: (0.85) (140-age) x weight / serum creatinine x 72. Age in years, weight in kg, and serum creatinine in mg/dL];
  • pregnant or nursing;
  • participating in another drug clinical trial within the last 2 months before the randomisation visit;
  • not ensured capability to perform the trial or to comply with the study protocol (e.g., mental retardation or severe inability to communicate);
  • any other uncontrolled clinically relevant disorder;
  • previous treatment with Eslicarbazepine Acetate;
  • a history or presence of bone marrow impairment or depression (introduced by protocol amendment No. 1);
  • a history or presence of acute intermittent porphyria (introduced by protocol amendment No. 1).

Patients receiving treatment for bipolar disorder or other central nervous system disorders at randomisation were excluded from randomisation. If the patients had previously used such medications the following restrictions had to be taken into account:

  • Patients treated with bipolar disorder preventive medication (for carbamazepine or oxcarbazepine see exclusion criteria), antidepressants, antipsychotic, anxiolytic, antiparkinsonian, and/or other potentially centrally acting drugs had to be washed-out for at least 2 days prior to randomisation (V2, Day 1).
  • Patients treated with lithium or valproate could only be randomised with plasma levels < 0.5 mmol/L and < 50 mg/L, respectively.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822678


Sponsors and Collaborators
Bial - Portela C S.A.
Investigators
Layout table for investigator information
Study Director: Patrício Soares-da-Silva, MD, PhD BIAL - Portela & Ca. SA

Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT01822678    
Other Study ID Numbers: BIA-2093-203
First Posted: April 2, 2013    Key Record Dates
Results First Posted: August 2, 2013
Last Update Posted: March 27, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Pathologic Processes
Eslicarbazepine acetate
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action